Latest Ratios: P/E Ratio -30.6x · EV/EBITDA N/A · ROE -163.8%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.6B | $5.2B | $516M | $345M | $216M | $177M | $94M | $109M | $243M | $141M | — |
| Enterprise Value | $5.7B | $5.3B | $592M | $352M | $227M | $107M | $83M | $90M | $227M | $139M | — |
| P/E Ratio → | -30.61 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 60.46 | 52.11 | 4.47 | 2.47 | 1.61 | 2.57 | 8.04 | 5.64 | 9.58 | 4.50 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -163.8% | -163.8% | -87.5% | -46.6% | -39.9% | -73.6% | -61.1% | -33.0% | -26.4% | -33.8% | -62.3% |
| ROA | -49.8% | -49.8% | -51.2% | -34.8% | -30.9% | -59.9% | -57.0% | -31.8% | -25.8% | -32.9% | -58.3% |
| ROIC | -80.4% | -80.4% | -50.3% | -34.1% | -41.1% | — | -1251.3% | -114.2% | -31.2% | -31.3% | — |
| ROCE | -54.2% | -54.2% | -58.0% | -38.3% | -31.2% | -59.6% | -61.4% | -34.9% | -28.0% | -32.2% | -62.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.94 | 1.94 | 0.85 | 0.27 | 0.26 | 0.22 | 0.02 | 0.01 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.30 | 0.65 | 0.05 | 0.08 | -1.01 | -0.97 | -0.96 | -0.63 | -0.08 | -1.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -9.32 | -9.32 | -9.87 | -10.97 | -18.70 | -22.45 | -79634.70 | -49089.94 | -67393.73 | -13.18 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.55 | 10.55 | 7.71 | 13.43 | 25.45 | 34.06 | 10.26 | 21.12 | 38.07 | 42.36 | 13.27 |
| Quick Ratio | 10.55 | 10.55 | 7.71 | 13.43 | 25.45 | 34.06 | 10.26 | 21.12 | 38.07 | 42.36 | 13.27 |
| Cash Ratio | 10.00 | 10.00 | 7.41 | 12.73 | 24.50 | 33.64 | 9.84 | 20.58 | 37.59 | 41.86 | 13.15 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $53M | $39M | $24M | $15M | $13M | $10M | $10M | $10M | $7M | $7M |
Binary clinical trial outcome
Based on reported figures, Celcuity trades at a price-to-book ratio of 52.22, which significantly exceeds the valuation of peers like Kymera Therapeutics, suggesting that the market is pricing in substantial intangible value derived from the CELsignia platform rather than current tangible assets or near-term earnings potential.
The elevated P/B ratio indicates that investors are assigning a high premium to the company's intellectual property and clinical pipeline. This valuation appears to be untethered from traditional earnings-based metrics, as the company remains pre-revenue and continues to generate significant net losses.
According to recent financial statements, Celcuity's ROIC has deteriorated to -32.4% in 2026Q1, reflecting a consistent trend of value destruction as the firm aggressively deploys capital into clinical trials without generating the operational returns necessary to offset the high costs of research and development.
The persistent negative ROIC highlights the structural challenge of a pre-revenue biotech firm where capital is consumed to build future value rather than generate current returns. Investors should monitor whether the company can eventually achieve a positive return on invested capital once the Gedatolisib therapeutic candidate reaches commercialization.
As reported in quarterly filings, the company's debt-to-equity ratio has surged to 3.65 in 2026Q1, a marked increase from 0.27 in 2023Q4, which indicates a growing reliance on external financing to sustain the intensive capital requirements of the ongoing VIKTORIA Phase 3 clinical trial program.
The rapid accumulation of debt relative to equity suggests that the company is increasingly leveraging its balance sheet to bridge the gap between clinical development and potential commercial revenue. This trend warrants close monitoring, as the rising debt service obligations could constrain future financial flexibility if clinical milestones are delayed.
Based on the company's reported figures, the current ratio has declined from 13.43 in 2023Q4 to 12.31 in 2026Q1, signaling that while the firm maintains a high liquidity position, the absolute cash runway is being consumed at an accelerating pace to support its clinical-stage research and development activities.
While the current ratio remains high compared to industrial peers, it is a misleading indicator of long-term solvency for a pre-revenue biotech firm. The true liquidity risk is better captured by the rate of cash burn, which continues to erode the company's cash reserves and necessitates future capital raises.
As indicated by the provided financial data, the use of P/E ratios to evaluate Celcuity is fundamentally flawed, as the company's negative earnings are a structural feature of its clinical-stage business model rather than a reflection of poor operational performance or a lack of market demand.
Investors should focus on cash burn and clinical trial milestones rather than P/E or net margin, which obscure the company's true progress. Using traditional profitability metrics for a pre-revenue firm like Celcuity risks misinterpreting necessary R&D investment as operational failure, leading to incorrect conclusions about the company's long-term viability.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CELC stock.
Celcuity Inc.'s current P/E ratio is -30.6x. This places it at the 50th percentile of its historical range.
Celcuity Inc.'s return on equity (ROE) is -163.8%. The historical average is -61.2%.
Based on historical data, Celcuity Inc. is trading at a P/E of -30.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.